Empowering customer engagement by informative billing: a European approach

Programmes aimed at improving end-use energy efficiency are a keystone in the market strategies of leading distribution system operators (DSOs) and energy retail companies and are increasing in application, soon expected to become a mainstream practice. Informative services based on electricity meter data collected for billing are powerful tools for energy savings in scale and increase customer engagement with the energy suppliers enabling the deployment of demand response programmes helping to optimise distribution grid operation. These services are completely in line with Europe’s 2020 strategy for overall energy performance improvement (cf. directives 2006/32/EC, 2009/72/EC, 2012/27/EU). The Intelligent Energy Europe project EMPOWERING involves 4 European utilities and an international team of university researchers, social scientists and energy experts for developing and providing insight based services and tools for 344.000 residential customers in Austria, France, Italy and Spain. The project adopts a systematic iterative approach of service development based on envisaging the utilities’, customers’ and legal requirements, and incorporates the feedback from testing in the design process. The technological solution provided by the leading partner CIMNE is scalable open source Big Data Analytics System coupled with the DSO’s information systems and delivering a range of value adding services for the customer, such as: - comparison with similar households - indications of performance improvements over time - consumption-weather dependence - detailed consumption visualisation and breakdown - personalised energy saving tips - alerts (high consumption, high bill, extreme temperature, etc.) The paper presents the development approach, describes the ICT system architecture and analyses the legal and regulatory context for providing this kind of services in the European Community. The limitations for third party data access, customer consent and data privacy are discussed, and how these have been overcome with the implementation of the “privacy by design” principle is explained

Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial

INTRODUCTION:Recent findings from onchocerciasis-endemic foci uphold that increasing ivermectin coverage reduces the epilepsy incidence, and anecdotal evidence suggests seizure frequency reduction in persons with onchocerciasis-associated epilepsy, when treated with ivermectin. We conducted a randomized clinical trial to assess whether ivermectin treatment decreases seizure frequency. METHODS:A proof-of-concept randomized clinical trial was conducted in the Logo health zone in the Ituri province, Democratic Republic of Congo, to compare seizure frequencies in onchocerciasis-infected persons with epilepsy (PWE) randomized to one of two treatment arms: the anti-epileptic drug phenobarbital supplemented with ivermectin, versus phenobarbital alone. The primary endpoint was defined as the probability of being seizure-free at month 4. A secondary endpoint was defined as >50% reduction in seizure frequency at month 4, compared to baseline. Both endpoints were analyzed using multiple logistic regression. In longitudinal analysis, the probability of seizure freedom during the follow-up period was assessed for both treatment arms by fitting a logistic regression model using generalized estimating equations (GEE). RESULTS:Ninety PWE enrolled between October and November 2017 were eligible for analysis. A multiple logistic regression analysis showed a borderline association between ivermectin treatment and being seizure-free at month 4 (OR: 1.652, 95% CI 0.975-2.799; p = 0.062). There was no significant difference in the probability of experiencing >50% reduction of the seizure frequency at month 4 between the two treatment arms. Also, treatment with ivermectin did not significantly increase the odds of being seizure-free during the individual follow-up visits. CONCLUSION:Whether ivermectin has an added value in reducing the frequency of seizures in PWE treated with AED remains to be determined. A larger study in persons with OAE on a stable AED regimen and in persons with recent epilepsy onset should be considered to further investigate the potential beneficial effect of ivermectin treatment in persons with OAE. TRIAL REGISTRATION:Registration: www.clinicaltrials.gov; NCT03052998